<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02736435</url>
  </required_header>
  <id_info>
    <org_study_id>RP-317-07302014</org_study_id>
    <nct_id>NCT02736435</nct_id>
  </id_info>
  <brief_title>Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound</brief_title>
  <official_title>Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thunder Bay Regional Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thunder Bay Regional Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the effectiveness of MR-HIFU for the treatment of&#xD;
      uterine fibroids in Northwestern Ontario, which is a rural and remote setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uterine fibroids are benign smooth muscle tumours of the muscular wall of the uterus that&#xD;
      affect 40 per cent of women. While the majority of fibroids are asymptomatic, fibroids may&#xD;
      cause menorrhagia, bulk symptoms (i.e. ureteric obstruction, urinary frequency and urgency,&#xD;
      bowel dysfunction), pain and in certain instances infertility.&#xD;
&#xD;
      Magnetic resonance image-guided high-intensity focused ultrasound (MR-HIFU) treatment of&#xD;
      fibroids is an established method for symptom alleviation with over 3000 women receiving&#xD;
      treatment worldwide. MR-HIFU is a non-invasive, non-surgical procedure that uses ultrasound&#xD;
      energy to thermally ablate the fibroid leading to a reduction in bleeding and in the size of&#xD;
      uterine fibroids over time. MR-HIFU it is not currently being used for the treatment of&#xD;
      symptomatic fibroids in Canada.&#xD;
&#xD;
      The Thunder Bay Regional Research Institute has one of the first clinically available MR-HIFU&#xD;
      equipment in Canada. In order to bring this technology into clinical practice, a knowledge&#xD;
      translation study is needed to demonstrate that MR-HIFU can treat symptomatic uterine&#xD;
      fibroids as successfully in Northwestern Ontario compared to urban centres where all of the&#xD;
      clinical trials have been conducted. The ability to screen and follow up women treated with&#xD;
      MR-HIFU with ultrasound rather than MRI would allow participants to receive follow up in&#xD;
      regional centres in Northwestern Ontario and it would be more cost effective from a health&#xD;
      system perspective. In addition, more research is needed to broaden the scope of treatment to&#xD;
      include fibroids greater than 8 cm such that more women could benefit from this non-surgical&#xD;
      fibroid management option.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lengthy delays and inadequate support to proceed.&#xD;
  </why_stopped>
  <start_date type="Actual">January 18, 2018</start_date>
  <completion_date type="Actual">January 18, 2018</completion_date>
  <primary_completion_date type="Actual">January 18, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in uterine fibroid symptom severity scale</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Assessing change from baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in short form McGill pain questionnaire</measure>
    <time_frame>24h, 72h, 6week, 3, 6, and 12 month</time_frame>
    <description>Assessing change from baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pictorial blood loss assessment chart</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Assessing change from baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in uterine fibroid symptom and health-related quality of life questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Assessing change from baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant use of alternative therapies for treatment of fibroids</measure>
    <time_frame>6 weeks, 3, 6, and 12 months</time_frame>
    <description>Questionnaire to assess if participants are selecting to use alternative treatments for relief of symptoms of uterine fibroids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MR Imaging to assess change in fibroid volume.</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Assessing change from baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MR Imaging to assess change in perfusion.</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Assessing change from baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound imaging to assess change in fibroid volume.</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Assessing change from baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound imaging to assess change in fibroid perfusion.</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Assessing change from baseline value</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Return to activity within 72 hours of treatment</measure>
    <time_frame>72 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in hemoglobin level</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Assessing change from baseline value</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Uterine Leiomyoma</condition>
  <arm_group>
    <arm_group_label>Fibroid dimension &lt; 8 cm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with a maximum fibroid dimension less than 8 cm and a total uterine volume less than 900 cc.&#xD;
Intervention: Treatment of fibroids with Magnetic Resonance Guided High Intensity Focused Ultrasound.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fibroid dimension &gt; 8 cm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with a maximum fibroid dimension greater than 8 cm or a total uterine volume greater than 900 cc.&#xD;
Intervention A: Pre-treated with 11.25mg leuprolide acetate for depot suspension for 3 months to reduce size of fibroids.&#xD;
Intervention B: Treatment with Magnetic Resonance Guided High Intensity Focused Ultrasound if fibroids decrease to treatable size of less than 8cm and uterine volume less than 900cc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Guided High Intensity Focused Ultrasound</intervention_name>
    <description>Direct treatment of uterine fibroids with MR-HIFU</description>
    <arm_group_label>Fibroid dimension &lt; 8 cm</arm_group_label>
    <arm_group_label>Fibroid dimension &gt; 8 cm</arm_group_label>
    <other_name>MR-HIFU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leuprolide acetate for depot suspension</intervention_name>
    <description>Treatment of uterine fibroids with leuprolide acetate prior to MR-HIFU</description>
    <arm_group_label>Fibroid dimension &gt; 8 cm</arm_group_label>
    <other_name>Lupron Depot</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged 18 to 50 years&#xD;
&#xD;
          -  Weight &lt;140kg&#xD;
&#xD;
          -  Pre or perimenopausal&#xD;
&#xD;
          -  Uterine size &lt;24 weeks&#xD;
&#xD;
          -  Cervical screen by Pap test: Normal, Low Grade Squamous Intraepithelial Lesion, or&#xD;
             Atypical Squamous Cells of Undetermined Significance as per Cancer Care Ontario&#xD;
             guidelines&#xD;
&#xD;
          -  Transformed symptom severity score ≥40&#xD;
&#xD;
          -  Willing to attend all study visits&#xD;
&#xD;
          -  Willing to complete evaluation forms&#xD;
&#xD;
          -  Willing and able to use reliable contraception;&#xD;
&#xD;
        MR-HIFU Criteria Trial Arm 1:&#xD;
&#xD;
          -  Minimum of 50% of fibroid volume accessible for treatment&#xD;
&#xD;
          -  Dominant fibroid ≤8 cm&#xD;
&#xD;
          -  Uterine volume &lt;900 cc&#xD;
&#xD;
          -  Total fibroid treatment volume &lt;250 cc&#xD;
&#xD;
          -  No more than 5 fibroids planned for ablation&#xD;
&#xD;
          -  Completely non-enhancing fibroids should not be treated&#xD;
&#xD;
        MR-HIFU Criteria Trial Arm 2:&#xD;
&#xD;
          -  Minimum of 50% of fibroid volume accessible for treatment&#xD;
&#xD;
          -  Dominant fibroid &gt;8 cm or uterine volume &gt;900 cc&#xD;
&#xD;
          -  Total fibroid treatment volume &lt;250 cc&#xD;
&#xD;
          -  No more than 5 fibroids planned for ablation&#xD;
&#xD;
          -  Completely non-enhancing fibroids should not be treated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other pelvic disease (endometriosis, ovarian tumor, acute pelvic disease, other mass)&#xD;
&#xD;
          -  Significant systemic disease even if well controlled&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  Abnormal uterine bleeding (participant can be included if an endometrial biopsy&#xD;
             confirms no hyperplasia or malignancy in the past 6 months)&#xD;
&#xD;
          -  Extensive scarring along anterior abdominal wall (&gt;50% of area)&#xD;
&#xD;
          -  Surgical clips or scar tissue in the path of the MR-HIFU beam&#xD;
&#xD;
          -  MRI contraindicated according to standard operating procedure&#xD;
&#xD;
          -  MRI contrast contraindicated (including renal insufficiency)&#xD;
&#xD;
          -  Calcifications around or throughout uterine tissues&#xD;
&#xD;
          -  Fibroids not quantifiable on MRI&#xD;
&#xD;
          -  Highly perfused or brighter than myometrium in T2-weighted MRI fibroids (Type 3&#xD;
             fibroids).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naana A Jumah, MD DPhil FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northern Ontario School of Medicine, Thunder Bay Regional Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Sciences Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol. 1991 May;77(5):720-5.</citation>
    <PMID>1901638</PMID>
  </reference>
  <reference>
    <citation>Gizzo S, Saccardi C, Patrelli TS, Ancona E, Noventa M, Fagherazzi S, Mozzanega B, D'Antona D, Nardelli GB. Magnetic resonance-guided focused ultrasound myomectomy: safety, efficacy, subsequent fertility and quality-of-life improvements, a systematic review. Reprod Sci. 2014 Apr;21(4):465-76. doi: 10.1177/1933719113497289. Epub 2013 Jul 18. Review.</citation>
    <PMID>23868442</PMID>
  </reference>
  <reference>
    <citation>Quinn SD, Vedelago J, Gedroyc W, Regan L. Safety and five-year re-intervention following magnetic resonance-guided focused ultrasound (MRgFUS) for uterine fibroids. Eur J Obstet Gynecol Reprod Biol. 2014 Nov;182:247-51. doi: 10.1016/j.ejogrb.2014.09.039. Epub 2014 Oct 6.</citation>
    <PMID>25445107</PMID>
  </reference>
  <reference>
    <citation>Smart OC, Hindley JT, Regan L, Gedroyc WG. Gonadotrophin-releasing hormone and magnetic-resonance-guided ultrasound surgery for uterine leiomyomata. Obstet Gynecol. 2006 Jul;108(1):49-54.</citation>
    <PMID>16816055</PMID>
  </reference>
  <reference>
    <citation>Stewart EA, Gostout B, Rabinovici J, Kim HS, Regan L, Tempany CM. Sustained relief of leiomyoma symptoms by using focused ultrasound surgery. Obstet Gynecol. 2007 Aug;110(2 Pt 1):279-87.</citation>
    <PMID>17666601</PMID>
  </reference>
  <reference>
    <citation>Thiburce AC, Frulio N, Hocquelet A, Maire F, Salut C, Balageas P, Bouzgarrou M, Hocké C, Trillaud H. Magnetic resonance-guided high-intensity focused ultrasound for uterine fibroids: Mid-term outcomes of 36 patients treated with the Sonalleve system. Int J Hyperthermia. 2015;31(7):764-70. doi: 10.3109/02656736.2015.1063169. Epub 2015 Sep 14.</citation>
    <PMID>26367772</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Magnetic Resonance Guided High Intensity Focused Ultrasound</keyword>
  <keyword>MR-HIFU</keyword>
  <keyword>Fibroids</keyword>
  <keyword>Leuprolide Acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

